Tango Therapeutics (NASDAQ: TNGX) net income
Tango Therapeutics reported a net loss of $101.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $130.3m. Earnings per share were −$0.87.
Tango Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$101.6m | — | −162.9% | −$0.87 |
| 2024 | −$130.3m | — | −309.7% | −$1.19 |
| 2023 | −$101.7m | — | −278.5% | −$1.08 |
| 2022 | −$108.2m | — | −435.1% | −$1.23 |
| 2021 | −$58.2m | — | −157.2% | −$0.94 |
| 2020 | −$52.0m | — | −678.8% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Tango Therapeutics net income compared with its sector
By net income for its latest fiscal year, Tango Therapeutics ranks 334th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Tango Therapeutics, −162.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 332nd | Prelude Therapeutics | −$99.5m | −819.6% |
| 333rd | Lexeo Therapeutics | −$100.0m | — |
| 334th | Tango Therapeutics | −$101.6m | −162.9% |
| 335th | ALX Oncology | −$101.7m | — |
| 336th | Perspective Therapeutics | −$103.1m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Tango Therapeutics
- How much did Tango Therapeutics earn in fiscal 2025?
- Tango Therapeutics reported a net loss of $101.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $130.3m.
- What are the earnings per share of Tango Therapeutics?
- They were −$0.87 in fiscal 2025, compared with −$1.19 in fiscal 2024.
- Where does Tango Therapeutics rank in its sector by net income?
- It ranks 334th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Tango Therapeutics come from?
- From the annual report (Form 10-K) that Tango Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Tango Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Tango Therapeutics: the Tango Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.